Nkarta, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
Phone
(925) 407-1049
Fiscal Year End
1231
EIN
474515206
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 424B5 Prospectus supplement | April 3, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 25, 2026 | View on SEC |
| 10-K Annual financial report | March 25, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | January 20, 2026 | View on SEC |
| 4 Insider stock transaction report | January 20, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
Annual Reports
10-K
March 25, 2026
- Pioneering 'off-the-shelf' natural killer cell therapies for cancer and autoimmune diseases.
- Strong cash position of $415 million providing operational runway into 2027.
Insider Trading
SELL
2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.